The Kinetochore as Target for Cancer Drug Development

  • Song-Tao Liu
  • Tim J. Yen


Due to diverse and complex genetic abnormalities in different cancers, there are no silver bullets in cancer treatment. According to the NCI (, chemotherapy, together with radiotherapy and surgery, are the three major modalities of cancer treatment.

As uncontrolled proliferation is the most distinctive characteristic of cancer cells, many anticancer drugs directly inhibit growth. These include drugs that target DNA or nucleotide metabolism and cell division. In a cell division cycle, mitosis is the phase during which duplicated sister chromatids physically separate from each other to produce two genetically identical daughter cells. Chemical compounds that interfere with this process should in principle be efficient inhibitors of cell proliferation. However, currently available anticancer drugs of this class are limited to two types of plant alkaloids: taxanes (docetaxel, paclitaxel) and vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine)....


Aurora Kinase Mitotic Arrest Kinetochore Protein Spindle Checkpoint Mitotic Checkpoint 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahmad, N., Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer. Faseb J, 2004. 18(1): 5–7.PubMedGoogle Scholar
  2. Altieri, D.C., The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol, 2006. 18(6): 609–15.PubMedGoogle Scholar
  3. Anand, S., S. Penrhyn-Lowe, and A.R. Venkitaraman, AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell, 2003. 3(1): 51–62.PubMedGoogle Scholar
  4. Andrews, P.D., et al., Aurora B regulates MCAK at the mitotic centromere. Dev Cell, 2004. 6(2): 253–68.PubMedGoogle Scholar
  5. Andrews, P.D., et al., Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol, 2003. 15(6): 672–83.PubMedGoogle Scholar
  6. Arnaud, L., J. Pines, and E.A. Nigg, GFP tagging reveals human Polo-like kinase 1 at the kinetochore/centromere region of mitotic chromosomes. Chromosoma, 1998. 107(6–7): 424–9.PubMedGoogle Scholar
  7. Ashar, H.R., et al., Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem, 2000. 275(39): 30451–7.PubMedGoogle Scholar
  8. Babu, J.R., et al., Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J Cell Biol, 2003. 160(3): 341–53.PubMedGoogle Scholar
  9. Baker, D.J., et al., BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet, 2004. 36(7): 744–9.PubMedGoogle Scholar
  10. Bansal, P.K., R. Abdulle, and K. Kitagawa, Sgt1 associates with Hsp90: an initial step of assembly of the core kinetochore complex. Mol Cell Biol, 2004. 24(18): 8069–79.PubMedGoogle Scholar
  11. Barr, F.A., H.H. Sillje, and E.A. Nigg, Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol, 2004. 5(6): 429–40.PubMedGoogle Scholar
  12. Bartek, J. and J. Lukas, Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 2003. 3(5): 421–9.PubMedGoogle Scholar
  13. Bischoff, J.R., et al., A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. Embo J, 1998. 17(11): 3052–65.PubMedGoogle Scholar
  14. Brunner, T.B., et al., Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res, 2003. 63(18): 5656–68.PubMedGoogle Scholar
  15. Burkard, M.E., et al., Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci USA, 2007. 104(11): 4383–8.Google Scholar
  16. Cahill, D.P., et al., Mutations of mitotic checkpoint genes in human cancers. Nature, 1998. 392(6673): 300-3.PubMedGoogle Scholar
  17. Carmena, M. and W.C. Earnshaw, The cellular geography of aurora kinases. Nat Rev Mol Cell Biol, 2003. 4(11): 842–54.PubMedGoogle Scholar
  18. Carvajal, R.D., A. Tse, and G.K. Schwartz, Aurora kinases: new targets for cancer therapy. Clin Cancer Res, 2006. 12(23): 6869–75.PubMedGoogle Scholar
  19. Cesario, A., et al., Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study. Clin Cancer Res, 2005. 11(5): 2026–37.PubMedGoogle Scholar
  20. Chan, G.K., S.T. Liu, and T.J. Yen, Kinetochore structure and function. Trends Cell Biol, 2005. 15(11): 589–98.PubMedGoogle Scholar
  21. Chan, G.K., Yen, T. J., The mitotic checkpoint: a signaling pathway that allows a single unattached kinetochore to inhibit mitotic exit, in Progress in Cell Cycle Research, L. Meijer, Jezequel, A., and Roberge, M., Editor. 2003, Editions “Life in Progress”: Roscoff, France. 431–439.Google Scholar
  22. Cheeseman, I.M., et al., The conserved KMN network constitutes the core microtubule-binding site of the kinetochore. Cell, 2006. 127(5): 983–97.PubMedGoogle Scholar
  23. Chen, Y., et al., HEC, a novel nuclear protein rich in leucine heptad repeats specifically involved in mitosis. Mol Cell Biol, 1997. 17(10): 6049–56.PubMedGoogle Scholar
  24. Ciferri, C., et al., Architecture of the human ndc80-hec1 complex, a critical constituent of the outer kinetochore. J Biol Chem, 2005. 280(32): 29088–95.PubMedGoogle Scholar
  25. Cleveland, D.W., Y. Mao, and K.F. Sullivan, Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell, 2003. 112(4): 407–21.PubMedGoogle Scholar
  26. Crespo, N.C., et al., The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem, 2001. 276(19): 16161–7.PubMedGoogle Scholar
  27. Crespo, N.C., et al., The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ, 2002. 9(7): 702–9.PubMedGoogle Scholar
  28. Cullinan, S.B. and L. Whitesell, Heat shock protein 90: a unique chemotherapeutic target. Semin Oncol, 2006. 33(4): 457–65.PubMedGoogle Scholar
  29. Dai, W. and J.P. Cogswell, Polo-like kinases and the microtubule organization center: targets for cancer therapies. Prog Cell Cycle Res, 2003. 5: 327–34.PubMedGoogle Scholar
  30. DeBonis, S., et al., In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther, 2004. 3(9): 1079–90.PubMedGoogle Scholar
  31. DeLuca, J.G., et al., hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells. J Cell Biol, 2002. 159(4): 549–55.PubMedGoogle Scholar
  32. DeLuca, J.G., et al., Kinetochore microtubule dynamics and attachment stability are regulated by Hec1. Cell, 2006. 127(5): 969–82.PubMedGoogle Scholar
  33. Ditchfield, C., et al., Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol, 2003. 161(2): 267–80.PubMedGoogle Scholar
  34. Dorer, R.K., et al., A small-molecule inhibitor of Mps1 blocks the spindle-checkpoint response to a lack of tension on mitotic chromosomes. Curr Biol, 2005. 15(11): 1070–6.PubMedGoogle Scholar
  35. Eckerdt, F., J. Yuan, and K. Strebhardt, Polo-like kinases and oncogenesis. Oncogene, 2005. 24(2): 267–76.PubMedGoogle Scholar
  36. Ganem, N.J., Z. Storchova, and D. Pellman, Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev, 2007. 17(2): 157–62.PubMedGoogle Scholar
  37. Garber, K., Divide and conquer: new generation of drugs targets mitosis. J Natl Cancer Inst, 2005. 97(12): 874–6.PubMedGoogle Scholar
  38. Giet, R., C. Petretti, and C. Prigent, Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol, 2005. 15(5): 241–50.PubMedGoogle Scholar
  39. Glinsky, G.V., O. Berezovska, and A.B. Glinskii, Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest, 2005. 115(6): 1503–21.PubMedGoogle Scholar
  40. Glover, D.M., et al., Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell, 1995. 81(1): 95–105.PubMedGoogle Scholar
  41. Goetz, M.P., et al., The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol, 2003. 14(8): 1169–76.PubMedGoogle Scholar
  42. Golsteyn, R.M., et al., Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol, 1995. 129(6): 1617–28.PubMedGoogle Scholar
  43. Golsteyn, R.M., The position of Chk1 in cancer research. Trends Cell Biol, 2001. 11(5): 191.PubMedGoogle Scholar
  44. Gumireddy, K., et al., ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell, 2005. 7(3): 275–86.PubMedGoogle Scholar
  45. Gurzov, E.N. and M. Izquierdo, RNA interference against Hec1 inhibits tumor growth in vivo. Gene Ther, 2006. 13(1): 1–7.PubMedGoogle Scholar
  46. Hanks, S., et al., Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet, 2004. 36(11): 1159–61.PubMedGoogle Scholar
  47. Harrington, E.A., et al., VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med, 2004. 10(3): 262–7.PubMedGoogle Scholar
  48. Hauf, S., et al., The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol, 2003. 161(2): 281–94.PubMedGoogle Scholar
  49. Hayama, S., et al., Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res, 2006. 66(21): 10339–48.PubMedGoogle Scholar
  50. Hernando, E., et al., Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature, 2004. 430(7001): 797–802.PubMedGoogle Scholar
  51. Huang, H., et al., Tripin/hSgo2 recruits MCAK to the inner centromere to correct defective kinetochore attachments. J Cell Biol, 2007. 177(3): 413–24.PubMedGoogle Scholar
  52. Huang, R.C., C.C. Chang, and D. Mold, Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. Semin Oncol, 2006. 33(4): 479–85.PubMedGoogle Scholar
  53. Hussein, D. and S.S. Taylor, Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci, 2002. 115(Pt 17): 3403–14.PubMedGoogle Scholar
  54. Jablonski, S.A., S.T. Liu, and T.J. Yen, Targeting the kinetochore for mitosis-specific inhibitors. Cancer Biol Ther, 2003. 2(3): 236–41.PubMedGoogle Scholar
  55. Jackson, J.R., et al., Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer, 2007. 7(2): 107–17.PubMedGoogle Scholar
  56. Jallepalli, P.V. and C. Lengauer, Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer, 2001. 1(2): 109–17.PubMedGoogle Scholar
  57. Joseph, J., et al., The RanGAP1-RanBP2 complex is essential for microtubule-kinetochore interactions in vivo. Curr Biol, 2004. 14(7): 611–7.PubMedGoogle Scholar
  58. Kaplan, K.B., et al., A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol, 2001. 3(4): 429–32.PubMedGoogle Scholar
  59. Keen, N. and S. Taylor, Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer, 2004. 4(12): 927–36.PubMedGoogle Scholar
  60. Kenny, L.M., et al., Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res, 2005. 65(21): 10104–12.PubMedGoogle Scholar
  61. Kitagawa, K., et al., SGT1 encodes an essential component of the yeast kinetochore assembly pathway and a novel subunit of the SCF ubiquitin ligase complex. Mol Cell, 1999. 4(1): 21–33.PubMedGoogle Scholar
  62. Kops, G.J., B.A. Weaver, and D.W. Cleveland, On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer, 2005. 5(10): 773–85.PubMedGoogle Scholar
  63. Kops, G.J., D.R. Foltz, and D.W. Cleveland, Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A, 2004. 101(23): 8699–704.Google Scholar
  64. Lenart, P., et al., The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol, 2007. 17(4): 304–15.PubMedGoogle Scholar
  65. Lens, S.M., G. Vader, and R.H. Medema, The case for Survivin as mitotic regulator. Curr Opin Cell Biol, 2006. 18(6): 616–22.PubMedGoogle Scholar
  66. Li, F. and M.G. Brattain, Role of the Survivin gene in pathophysiology. Am J Pathol, 2006. 169(1): 1–11.PubMedGoogle Scholar
  67. Li, L., et al., Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther, 2007. 14(10): 814–27.PubMedGoogle Scholar
  68. Li, X., et al., Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. J Biol Chem, 2004. 279(45): 47201–11.PubMedGoogle Scholar
  69. Liu, S.T., J.M. van Deursen, and T.J. Yen, The role of mitotic checkpoint in maintaining genomic stability. Curr Top Dev Biol, 2003. 58: 27–51.PubMedGoogle Scholar
  70. Liu, Y., et al., Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem, 2007. 282(4): 2505–11.PubMedGoogle Scholar
  71. Lou, Y., et al., NEK2A interacts with MAD1 and possibly functions as a novel integrator of the spindle checkpoint signaling. J Biol Chem, 2004. 279(19): 20049–57.PubMedGoogle Scholar
  72. Martin-Lluesma, S., V.M. Stucke, and E.A. Nigg, Role of hec1 in spindle checkpoint signaling and kinetochore recruitment of mad1/mad2. Science, 2002. 297(5590): 2267–70.PubMedGoogle Scholar
  73. Mayer, T.U., et al., Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science, 1999. 286(5441): 971–4.PubMedGoogle Scholar
  74. McEwen, B.F., et al., CENP-E is essential for reliable bioriented spindle attachment, but chromosome alignment can be achieved via redundant mechanisms in mammalian cells. Mol Biol Cell, 2001. 12(9): 2776–89.PubMedGoogle Scholar
  75. McInnes, C., et al., Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol, 2006. 2(11): 608–17.PubMedGoogle Scholar
  76. Meraldi, P., R. Honda, and E.A. Nigg, Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. Embo J, 2002. 21(4): 483–92.PubMedGoogle Scholar
  77. Meraldi, P., V.M. Draviam, and P.K. Sorger, Timing and checkpoints in the regulation of mitotic progression. Dev Cell, 2004. 7(1): 45–60.PubMedGoogle Scholar
  78. Michel, L., et al., Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A, 2004. 101(13): 4459–64.Google Scholar
  79. Michel, L.S., et al., MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature, 2001. 409(6818): 355–9.PubMedGoogle Scholar
  80. Munster, P.N., et al., Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res, 2001. 61(7): 2945–52.PubMedGoogle Scholar
  81. Munster, P.N., et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res, 2001. 7(8): 2228–36.PubMedGoogle Scholar
  82. Niikura, Y., et al., 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation. Oncogene, 2006. 25(30): 4133–46.PubMedGoogle Scholar
  83. Niikura, Y., et al., BUB1 mediation of caspase-independent mitotic death determines cell fate. J Cell Biol, 2007. 178(2): 283–96.PubMedGoogle Scholar
  84. Orr, G.A., et al., Mechanisms of Taxol resistance related to microtubules. Oncogene, 2003. 22(47): 7280–95.PubMedGoogle Scholar
  85. Ota, T., et al., Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res, 2002. 62(18): 5168–77.PubMedGoogle Scholar
  86. Peters, U., et al., Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol, 2006. 2(11): 618–26.PubMedGoogle Scholar
  87. Pichler, A., et al., The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell, 2002. 108(1): 109–20.PubMedGoogle Scholar
  88. Plescia, J., et al., Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 2005. 7(5): 457–68.PubMedGoogle Scholar
  89. Plyte, S. and A. Musacchio, PLK1 inhibitors: setting the mitotic death trap. Curr Biol, 2007. 17(8): R280–R3.PubMedGoogle Scholar
  90. Powers, M.V. and P. Workman, Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer, 2006. 13( Suppl 1): S125–S35.PubMedGoogle Scholar
  91. Prudhomme, M., Novel Checkpoint 1 Inhibitors. Recent Patents on Anti-Cancer Drug Discovery, 2006. 1(1): 55–68.PubMedGoogle Scholar
  92. Putkey, F.R., et al., Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell, 2002. 3(3): 351–65.PubMedGoogle Scholar
  93. Rieder, C.L. and E.D. Salmon, The vertebrate cell kinetochore and its roles during mitosis. Trends Cell Biol, 1998. 8(8): 310–8.PubMedGoogle Scholar
  94. Rieder, C.L., The formation, structure, and composition of the mammalian kinetochore and kinetochore fiber. Int Rev Cytol, 1982. 79: 1–58.PubMedGoogle Scholar
  95. Rojanala, S., et al., The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther, 2004. 3(4): 451–7.PubMedGoogle Scholar
  96. Roninson, I.B., E.V. Broude, and B.D. Chang, If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat, 2001. 4(5): 303–13.PubMedGoogle Scholar
  97. Rowinsky, E.K. and E. Calvo, Novel agents that target tublin and related elements. Semin Oncol, 2006. 33(4): 421–35.PubMedGoogle Scholar
  98. Sasai, K., et al., Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton, 2004. 59(4): 249–63.PubMedGoogle Scholar
  99. Schafer-Hales, K., et al., Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther, 2007. 6(4): 1317–28.PubMedGoogle Scholar
  100. Schmidt, M., et al., Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep, 2005. 6(9): 866–72.PubMedGoogle Scholar
  101. Sotillo, R., et al., Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell, 2007. 11(1): 9–23.PubMedGoogle Scholar
  102. Srethapakdi, M., et al., Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res, 2000. 60(14): 3940–6.PubMedGoogle Scholar
  103. Steegmaier, M., et al., BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol, 2007. 17(4): 316–22.PubMedGoogle Scholar
  104. Steensgaard, P., et al., Sgt1 is required for human kinetochore assembly. EMBO Rep, 2004. 5(6): 626–31.PubMedGoogle Scholar
  105. Stevenson, C.S., et al., The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther, 2002. 303(2): 858–66.PubMedGoogle Scholar
  106. Strebhardt, K. and A. Ullrich, Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer, 2006. 6(4): 321–30.PubMedGoogle Scholar
  107. Tanudji, M., et al., Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay. Mol Biol Cell, 2004. 15(8): 3771–81.PubMedGoogle Scholar
  108. Tao, Z.F. and N.H. Lin, Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med Chem, 2006. 6(4): 377–88.PubMedGoogle Scholar
  109. Tatsuka, M., et al., Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene, 2005. 24(6): 1122–7.PubMedGoogle Scholar
  110. Tomonaga, T., et al., Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res, 2005. 65(11): 4683–9.PubMedGoogle Scholar
  111. Tomonaga, T., et al., Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res, 2003. 63(13): 3511–6.PubMedGoogle Scholar
  112. Torrance, C.J., et al., Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol, 2001. 19(10): 940–5.PubMedGoogle Scholar
  113. Torres, K. and S.B. Horwitz, Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res, 1998. 58(16): 3620–6.PubMedGoogle Scholar
  114. Vader, G., R.H. Medema, and S.M. Lens, The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol, 2006. 173(6): 833–7.PubMedGoogle Scholar
  115. Vagnarelli, P. and W.C. Earnshaw, Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma, 2004. 113(5): 211–22.PubMedGoogle Scholar
  116. Vassilev, L.T., MDM2 inhibitors for cancer therapy. Trends Mol Med, 2007. 13(1): 23–31.PubMedGoogle Scholar
  117. Wang, Q., et al., BUBR1 deficiency results in abnormal megakaryopoiesis. Blood, 2004. 103(4): 1278–85.PubMedGoogle Scholar
  118. Wang, Z., et al., Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res, 2004. 64(9): 2998–3001.PubMedGoogle Scholar
  119. Warner, S.L., P.J. Gray, and D.D. Von Hoff, Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol, 2006. 33(4): 436–48.PubMedGoogle Scholar
  120. Watanabe, Y. and T.S. Kitajima, Shugoshin protects cohesin complexes at centromeres. Philos Trans R Soc Lond B Biol Sci, 2005. 360(1455): 515–21, discussion 521.PubMedGoogle Scholar
  121. Weaver, B.A. and D.W. Cleveland, Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell, 2005. 8(1): 7–12.PubMedGoogle Scholar
  122. Weaver, B.A. and D.W. Cleveland, Does aneuploidy cause cancer? Curr Opin Cell Biol, 2006. 18(6): 658–67.PubMedGoogle Scholar
  123. Weaver, B.A., et al., Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell, 2007. 11(1): 25–36.PubMedGoogle Scholar
  124. Wei, R.R., et al., Structure of a central component of the yeast kinetochore: the Spc24p/Spc25p globular domain. Structure, 2006. 14(6): 1003–9.PubMedGoogle Scholar
  125. Wei, R.R., J. Al-Bassam, and S.C. Harrison, The Ndc80/HEC1 complex is a contact point for kinetochore-microtubule attachment. Nat Struct Mol Biol, 2007. 14(1): 54–9.PubMedGoogle Scholar
  126. Wilson, L. and M.A. Jordan, Microtubule dynamics: taking aim at a moving target. Chem Biol, 1995. 2(9): 569–73.PubMedGoogle Scholar
  127. Yang, H., et al., Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett, 2005. 579(16): 3385–91.PubMedGoogle Scholar
  128. Yuen, K.W., B. Montpetit, and P. Hieter, The kinetochore and cancer: what's the connection? Curr Opin Cell Biol, 2005. 17(6): 576–82.PubMedGoogle Scholar
  129. Zachos, G., et al., Chk1 is required for spindle checkpoint function. Dev Cell, 2007. 12(2): 247–60.PubMedGoogle Scholar
  130. Zhou, B.B. and E.A. Sausville, Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res, 2003. 5: 413–21.PubMedGoogle Scholar
  131. Zhou, B.B., H.J. Anderson, and M. Roberge, Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther, 2003. 2(4 Suppl 1): S16–S22.PubMedGoogle Scholar
  132. Zhou, H., et al., Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet, 1998. 20(2): 189–93.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Fox Chase Cancer CenterPhiladelphiaU.S.A

Personalised recommendations